Primary Application
For what




Source

For whom

All Trans Retinoic Acid (ATRA) is FDA approved in the treatment of promyelocytic leukemia. ATRA is a strong differentiating agent. As such, ATRA has potential as a therapy in a number of cancers, especially in the context of IC medicines. ATRA binds to retinoic acid receptors, and subsequently activates DNA transcription activity to move immature (e.g. malignant) cells toward normal maturation. Consider the use of ATRA in cases of cancer and precancerous lesions, including polyps, actinic keratosis, and others.
Similar ICs
291
37.9 k
9
603
157
50.1 k
171
102 k
118
29.9 k
10
371
354
47.6 k
440
127 k
157
50.7 k
430
72 k
Please select language
Select